



04. 24. 06

Attorney Docket No. VPI/02-115 US

DFY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/696,862  
Confirmation No.: 8080  
Filing Date: October 30, 2003  
Examiner: Venkataram Balasubramanian  
Group Art Unit: 1624  
Applicants: Jingrong Cao et al.  
For: COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER  
PROTEIN KINASES

April 21, 2006  
Cambridge, Massachusetts

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

☒ Copies of references Citation Nos. C1-C9 is attached.

☐ Copy(ies) of references Citation No(s). \_\_\_\_\_ was/were filed in application U.S. Application No(s). \_\_\_\_\_ filed \_\_\_\_\_, from which this application claims priority under 35 U.S.C. § 120.

☐ A copy of the International Search Report received in the corresponding PCT Application No. \_\_\_\_\_ is attached herewith.

- (b) ☐ No fee is believed due because:

☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.

☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.

☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

04/25/2006 WASFAW1 00000021 500725 10696862

01 FC:1806 180.00 DA

- ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c) ☒ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☒ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- ☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

Respectfully submitted,




---

Daniel A. Pearson, Reg. No. 58,053  
Agent for Applicants  
Karen E. Brown, Reg. No. 43,866  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6790  
Fax: (617) 444-6483  
Customer No. 27916

I hereby certify that this correspondence and any documents referred to as attached hereto is/are being deposited with the U.S. Postal Service with sufficient postage as Express Mail in an envelope addressed to:  
Mail Stop Amendment, Commissioner for Patents,  
P.O. Box 1450, Alexandria, VA 22313-1450 on April 21, 2006.

Lisa M. Romano

Typed or printed name of person signing this certificate



Signature



<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	10/696,862
	<b>Filing Date</b>	October 30, 2003
	<b>First Named Inventor</b>	Jingrong Cao
	<b>Group Art Unit</b>	1624
	<b>Examiner Name</b>	Venkataram Balasubramanian
	<b>Attorney Docket Number</b>	VPI/02-115 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Hoshino et al., "Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors," <i>Oncogene</i> , 18:813-22 (1999).
	C2	Frey et al., "TGF-beta regulation of mitogen-activated protein kinases in human breast cancer cells," <i>Cancer Letters</i> , 117(1):41-50 (1997).
	C3	Putz et al., "Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines," <i>Cancer Research</i> , 59(1):227-33 (1999).
	C4	Kortylewski et al., "Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells," <i>Biochemical Journal</i> , 357(Pt 1):297-303 (2001).
	C5	Hirooka et al., "Therapeutic potential of Rho-kinase inhibitors in cardiovascular diseases," <i>Am. J. Cardiovasc Drugs</i> , 5(1): 31-39 (2005).
	C6	Mueller et al., "RHO kinase, a promising drug target for neurological disorders," <i>Nature Reviews, Drug Discovery</i> , 4:387-398 (2005).
	C7	Doble et al., "GSK-3: tricks of the trade for a multi-tasking kinase," <i>Journal of Cell Science</i> , 116:1175-1186 (2003).
	C8	Chang et al., "Role of cAMP-dependent pathway in eosinophil apoptosis and survival," <i>Cell. Immunology</i> , 203(1):29-38 (2000).
	C9	Plotkin et al., "Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3," <i>J. Pharm. Exp. Ther.</i> 305:974-980 (2003).

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.